Ascendis Pharma AS Company Profile (NASDAQ:ASND)

About Ascendis Pharma AS

Ascendis Pharma AS logoAscendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. The Company's subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma and Endocrinology Division A/S (Denmark).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ASND
  • CUSIP:
Key Metrics:
  • Previous Close: $20.66
  • 50 Day Moving Average: $18.70
  • 200 Day Moving Average: $16.10
  • 52-Week Range: $11.92 - $21.70
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.79
  • P/E Growth: -0.26
  • Market Cap: $506.13M
  • Outstanding Shares: 25,193,000
  • Beta: 0.09
Additional Links:
Companies Related to Ascendis Pharma AS:

Analyst Ratings

Consensus Ratings for Ascendis Pharma AS (NASDAQ:ASND) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $29.00 (42.79% upside)

Analysts' Ratings History for Ascendis Pharma AS (NASDAQ:ASND)
Show:
DateFirmActionRatingPrice TargetDetails
9/26/2016WedbushInitiated CoverageOutperform$34.00View Rating Details
9/2/2016Leerink SwannReiterated RatingBuyView Rating Details
2/23/2015Bank of America Corp.Initiated CoverageBuyView Rating Details
2/23/2015Wells Fargo & Co.Initiated CoverageOutperform$26.00View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Ascendis Pharma AS (NASDAQ:ASND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
8/31/2016Q216($0.69)($0.59)$1.11 millionViewListenView Earnings Details
5/20/2016Q1($0.55)($0.92)ViewN/AView Earnings Details
11/12/2015Q315($0.57)($0.32)ViewN/AView Earnings Details
8/24/2015Q2($0.48)($0.73)ViewN/AView Earnings Details
5/18/2015Q115($0.37)$0.07$2.24 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ascendis Pharma AS (NASDAQ:ASND)
Current Year EPS Consensus Estimate: $-3.14 EPS
Next Year EPS Consensus Estimate: $-2.31 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.55)($0.55)($0.55)
Q2 20161($0.77)($0.77)($0.77)
Q3 20162($0.87)($0.66)($0.77)
Q4 20162($0.89)($0.66)($0.78)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ascendis Pharma AS (NASDAQ:ASND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ascendis Pharma AS (NASDAQ:ASND)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Ascendis Pharma AS (NASDAQ:ASND)
DateHeadline
nasdaq.com logoEuropean ADRs Edge Lower as Telecommunication Stocks See Mixed Fortunes (NASDAQ:ASND)
www.nasdaq.com - September 27 at 3:36 PM
nasdaq.com logoEuropean ADRs Edge Lower as Banks Retreat (NASDAQ:ASND)
www.nasdaq.com - September 26 at 3:43 PM
streetinsider.com logoWedbush Starts Ascendis Pharma (ASND) at Outperform (NASDAQ:ASND)
www.streetinsider.com - September 26 at 3:43 PM
finance.yahoo.com logoCoverage initiated on Ascendis Pharma by Wedbush (NASDAQ:ASND)
finance.yahoo.com - September 26 at 3:43 PM
finance.yahoo.com logoAscendis Pharma A/S (ASND): Moving Average Crossover Alert (NASDAQ:ASND)
finance.yahoo.com - September 26 at 3:43 PM
publicnow.com logoAscendis Pharma A/S Announces Webcast of R&D Update (NASDAQ:ASND)
www.publicnow.com - September 23 at 8:30 AM
finance.yahoo.com logoAscendis Pharma A/S Announces Participation in 2016 Morgan Stanley Global Healthcare Conference on September 14 (NASDAQ:ASND)
finance.yahoo.com - September 13 at 8:27 AM
finance.yahoo.com logoAscendis Pharma A/S Announces Multiple TransCon Growth Hormone Presentations at the European Society of Paediatric Endocrinology Annual Meeting (NASDAQ:ASND)
finance.yahoo.com - September 9 at 8:25 AM
reuters.com logoBRIEF-Ascendis Pharma reports Q2 loss per share EUR 0.53 (NASDAQ:ASND)
www.reuters.com - September 1 at 12:03 PM
publicnow.com logoAscendis Pharma A/S Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:ASND)
www.publicnow.com - September 1 at 12:03 PM
biz.yahoo.com logoQ2 2016 Ascendis Pharma A/S Earnings Release - After Market Close (NASDAQ:ASND)
biz.yahoo.com - August 31 at 8:24 AM
finance.yahoo.com logoCan the Rally in Ascendis Pharma (ASND) Shares Continue? (NASDAQ:ASND)
finance.yahoo.com - August 26 at 11:43 AM
live-pr.com logoNew Report Available: Ascendis Pharma A/S (ASND) - Financial and Strategic SWOT Analysis Review (NASDAQ:ASND)
www.live-pr.com - August 22 at 8:44 PM
publicnow.com logoAscendis Pharma A/S to Report Second Quarter 2016 Financial Results and Host Conference Call on August 31 (NASDAQ:ASND)
www.publicnow.com - August 19 at 11:59 AM
businesswire.com logoSymphogen’s Founding CEO Kirsten Drejer Steps Down and Becomes Executive Director (NASDAQ:ASND)
www.businesswire.com - August 18 at 12:00 PM
finance.yahoo.com logoAscendis Pharma A/S Announces R&D Update to Review Expanded Pipeline and Long-term Strategic Outlook (NASDAQ:ASND)
finance.yahoo.com - August 15 at 9:08 PM
News IconAscendis Pharma begins phase 3 study of transcon growth hormone in children with GHD (NASDAQ:ASND)
www.pharmabiz.com - August 13 at 11:48 AM
seekingalpha.com logoAscendis Pharma commences late-stage study supporting lead product candidate (NASDAQ:ASND)
seekingalpha.com - August 12 at 12:11 PM
News IconAscendis Pharma starts phase 3 pediatric GHD study (NASDAQ:ASND)
www.bioportfolio.com - August 12 at 12:11 PM
prnewswire.com logoAscendis Pharma A/S Initiates Phase 3 Registration Trial for TransCon Growth ... (NASDAQ:ASND)
www.prnewswire.com - August 12 at 12:11 PM
streetinsider.com logoAscendis Pharma (ASND) Initiates Phase 3 Trial for TransCon Growth Hormone in Children with GHD (NASDAQ:ASND)
www.streetinsider.com - August 12 at 12:11 PM
publicnow.com logoAscendis Pharma A/S Initiates Phase 3 Registration Trial for TransCon Growth Hormone in Children with Growth Hormone Deficiency (NASDAQ:ASND)
www.publicnow.com - August 11 at 12:51 PM
News IconAscendis Pharma appoints Scott T. Smith as CFO (NASDAQ:ASND)
www.poandpo.com - August 9 at 10:12 PM
streetinsider.com logoAscendis Pharma (ASND) Names New CFO (NASDAQ:ASND)
www.streetinsider.com - August 8 at 3:39 PM
publicnow.com logoAscendis Pharma A/S Appoints Scott T. Smith as Chief Financial Officer (NASDAQ:ASND)
www.publicnow.com - August 8 at 8:24 AM
sbwire.com logoMarket Report, "Prostaglandin E2 Receptor EP2 Subtype - Pipeline Review, H1 2016", Published (NASDAQ:ASND)
www.sbwire.com - July 13 at 11:44 AM
insidermonkey.com logoAscendis Pharma (ASND): OrbiMed Advisors Adds More Shares (NASDAQ:ASND)
www.insidermonkey.com - July 5 at 8:23 AM
insidermonkey.com logoOrbiMed Advisors Buys Some More Ascendis Pharma (ASND) Shares (NASDAQ:ASND)
www.insidermonkey.com - June 26 at 1:59 PM
capitalcube.com logoAscendis Pharma A/S :ASND-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016 (NASDAQ:ASND)
www.capitalcube.com - May 26 at 11:15 AM
publicnow.com logoAscendis Pharma A/S Reports First Quarter 2016 Financial Results (NASDAQ:ASND)
www.publicnow.com - May 19 at 4:52 PM
finance.yahoo.com logo9:04 am Ascendis Pharma appointed Jonathan Leff, M.D. as Chief Medical Officer (NASDAQ:ASND)
finance.yahoo.com - February 25 at 9:04 AM
finance.yahoo.com logoAscendis Pharma A/S Appoints Jonathan A. Leff, M.D. as Chief Medical Officer (NASDAQ:ASND)
finance.yahoo.com - February 25 at 9:00 AM
finance.yahoo.com logoAscendis Pharma A/S to Present at the Leerink Partners Global Healthcare Conference (NASDAQ:ASND)
finance.yahoo.com - February 3 at 5:00 PM
us.rd.yahoo.com logoAscendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency (NASDAQ:ASND)
us.rd.yahoo.com - January 14 at 11:25 AM
us.rd.yahoo.com logoAscendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time (NASDAQ:ASND)
us.rd.yahoo.com - January 14 at 11:25 AM
us.rd.yahoo.com logoAscendis Pharma A/S Reports Second Quarter 2015 Financial Results (NASDAQ:ASND)
us.rd.yahoo.com - January 14 at 11:25 AM
us.rd.yahoo.com logoJacob Gottlieb Adds To Position In Ascendis Pharma A/S (ASND); Armistice Capital Increases Stake In Demand Media Inc (DMD) (NASDAQ:ASND)
us.rd.yahoo.com - January 14 at 11:25 AM
us.rd.yahoo.com logoAscendis Pharma A/S to Present at Three Upcoming Investor Conferences (NASDAQ:ASND)
us.rd.yahoo.com - January 14 at 11:25 AM
us.rd.yahoo.com logoAscendis Pharma A/S Earnings Q2, 2015 (NASDAQ:ASND)
us.rd.yahoo.com - January 14 at 11:25 AM
us.rd.yahoo.com logoAscendis Pharma A/S Reports Third Quarter 2015 Financial Results (NASDAQ:ASND)
us.rd.yahoo.com - January 14 at 11:25 AM
us.rd.yahoo.com logoTwo Healthcare-Focused Funds Buy More Shares Of 2 Promising Companies, While Activist Cashes Out Of IT Company (NASDAQ:ASND)
us.rd.yahoo.com - January 14 at 11:25 AM
us.rd.yahoo.com logoHow Do Hedge Funds Feel About AK Steel Holding Corporation (AKS)? (NASDAQ:ASND)
us.rd.yahoo.com - January 14 at 11:25 AM
us.rd.yahoo.com logoAscendis Pharma A/S Earnings Analysis: Q3, 2015 By the Numbers (NASDAQ:ASND)
us.rd.yahoo.com - January 14 at 11:25 AM
finance.yahoo.com logoASCENDIS PHARMA A/S Financials (NASDAQ:ASND)
finance.yahoo.com - December 8 at 1:08 PM
finance.yahoo.com logoAscendis Pharma A/S to Present at the Stifel 2015 Healthcare Conference (NASDAQ:ASND)
finance.yahoo.com - November 11 at 4:05 PM
finance.yahoo.com logoAusnutria Dairy Corporation Ltd 2015 Interim Gross Profit and Gross Profit Margin Increased by Approximately 7.3% and 3.0% Points Respectively (NASDAQ:ASND)
finance.yahoo.com - August 26 at 3:54 AM
finance.yahoo.com logoWill OmniVision's (OVTI) Earnings Surprise Estimates in Q1? (NASDAQ:ASND)
finance.yahoo.com - August 25 at 9:20 AM

Social

Ascendis Pharma AS (NASDAQ:ASND) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff